Division of Urologic Surgery, Duke Cancer Institute, Durham, NC, USA.
Eur Urol Focus. 2022 May;8(3):641-642. doi: 10.1016/j.euf.2022.05.001. Epub 2022 May 27.
Biomarkers are now ubiquitous in prostate cancer care. In addition to longstanding use of prostate-specific antigen, we now have secondary serum-, urine-, and tissue-based markers that help in optimizing patient care and patient compliance with therapeutic recommendations. The ship has sailed: these markers are useful and are here to stay.
生物标志物现在已经在前列腺癌的治疗中无处不在。除了长期使用的前列腺特异性抗原外，我们现在还有基于血清、尿液和组织的次要标志物，这些标志物有助于优化患者的治疗和提高患者对治疗建议的依从性。大势所趋：这些标志物是有用的，而且会继续存在。
